Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1040-1046

  Ruane, Peter J ^a   Ain, Dani ^a   Stryker, Richard ^a   Meshrekey, Raymond ^a   Soliman, Mina ^a   Wolfe, Peter R ^a   Riad, Joseph ^a   Mikhail, Sameh ^a   Kersey, Kathryn ^b   Jiang, Deyuan ^b   Massetto, Benedetta ^b   Doehle, Brian ^b   Kirby, Brian J ^b   Knox, Steven J ^b   McHutchison, John G ^b   Symonds, William T ^b  

^a Ruane Medical and Liver Health Institute   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; GLUCOSE; HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; RNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN;

ABDOMINAL DISTENSION; ADULT; AGED; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE MODEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EGYPTIAN; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OROPHARYNX PAIN; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; EGYPT; ETHNOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROCEDURES; UNITED STATES; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; RNA REPLICASE; RNA, VIRAL; SOFOSBUVIR; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84927796279     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.10.044     Document Type: Article

References (24)

1. M.A. Khattab, P. Ferenci, S.J. Hadziyannis, M. Colombo, M.P. Manns, and P.L. Almasio Management of hepatitis C virus genotype 4: recommendations of an international expert panel J Hepatol 54 2011 1250 1262
2. J.M. Wantuck, A. Ahmed, and M.H. Nguyen Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6 Aliment Pharmacol Ther 39 2014 137 147
3. S.C. Ray, R.R. Arthur, A. Carella, J. Bukh, and D.L. Thomas Genetic epidemiology of hepatitis C virus throughout Egypt J Infect Dis 182 2000 698 707
4. J. Guerra, M. Garenne, M.K. Mohamed, and A. Fontanet HCV burden of infection in Egypt: results from a nationwide survey J Viral Hepat 19 2012 560 567
5. C. Frank, M.K. Mohamed, G.T. Strickland, D. Lavanchy, R.R. Arthur, and L.S. Magder The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Lancet 355 2000 887 891
6. M.R. Rao, A.B. Naficy, M.A. Darwish, N.M. Darwish, E. Schisterman, and J.D. Clemens Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt BMC Infect Dis 2 2002 29 [epub]
7. G. Esmat, M. El Raziky, M. El Kassas, M. Hassany, and M.E. Gamil Treatment of chronic HCV genotype 4 infection Curr Hepat Rep 11 2012 250 255
8. A.J. Muir The rapid evolution of treatment strategies for hepatitis C Am J Gastroenterol 109 2014 628 635
9. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
10. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
11. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. < http://www.hcvguidelines.org/ >; 2014 [accessed 2.06.14].
12. EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
13. World Health Organization. Guidelines for screening, care and treatment of persons with hepatitis C infection. < http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ >; 2014. [published April 2014, accessed June 2, 2014].
14. B. Kirby, T. Gordi, W.T. Symonds, B.P. Kearney, and A. Mathias Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects Hepatology 58 2013 746A
15. C. Moreno, C. Hezode, P. Marcellin, S. Bourgeois, S. Francque, and D. Samuel Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: SVR12 results of a phase III trial J Hepatol 60 2014 S535
16. C. Hezode, P. Marcellin, S. Pol, T. Hassanein, K. Fleischer-Stepniewska, and T. Baykal Results from the phase 2 PEARL-I study: Interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection J Hepatol 60 2014 S24
17. T. Hassanein, K. Sims, M. Bennett, N. Gitlin, E. Lawitz, and T. Nguyen All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection J Hepatol 60 2014 S472
18. D. Roulot, V. Bourcier, V. Grando, P. Deny, Y. Baazia, and H. Fontaine Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection J Viral Hepat 14 2007 460 467
19. R. Moucari, M.-P. Ripualt, M. Martinot-Peignoux, H. Voitot, A.C. Cardoso, and C. Stern Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 Gut 58 2009 1662 1669
20. D. Dimitroulopoulos, I. Elefsiniotis, C. Pavlidis, D. Xinopoulos, K. Tsamakidis, and S. Patsavela European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response Hepat Mon 10 2010 193 198
21. V. Papastergiou, D. Dimitroulopoulos, L. Skorda, P. Lisgos, I. Ketikoglou, and N. Kostas Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 84 2012 1217 1223
22. N. Antaki, A. Craxi, S. Kamal, R. Moucari, S. Van der Merwe, and S. Haffar The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report Liver Int 2010 30342 30355
23. T. Asselah, S. De Muynck, P. Broët, J. Masliah-Planchon, M. Blanluet, and I. Bièche IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C J Hepatol 56 2012 527 532
24. T. Asselah, P.V. Perumalswami, and D. Dieterich Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity Liver Int 34 2014 1447 1451